Various inhibitors of molecules in the PI3K/AKT pathway are undergoing pre‐clinical validation for many tumour types.28, 29 INPP4B may also be a potential candidate for adjuvant therapy of cervical cancer and other tumours that are activated in the PI3K pathway. Here, AKT1 is linked to cervical carcinoma.